Skip to content
Brand AI

Incyte

Request correction

Corporate brand

Unclaimed

Incyte is a U.S.-based biopharmaceutical company that discovers, develops and commercializes medicines in hematology, oncology, inflammation and autoimmunity.

Last updated November 4, 2026

AI crawler reads

No AI crawler has read this profile yet.

Overview

Incyte is an American biopharmaceutical company headquartered in Wilmington, Delaware. Its business is centered on the discovery, development and commercialization of prescription medicines for serious diseases, with its principal therapeutic focus spanning hematology, oncology, inflammation and autoimmunity. The company operates across North America, Europe and Asia, combining internal research and development with partnerships, licenses and selected acquisitions. The company was founded and incorporated in Delaware in 1991 by Roy A. Whitfield. It initially operated as a genomics and biotechnology-information company, developing genomic databases, research tools and related intellectual property for pharmaceutical companies, biotechnology businesses and academic institutions. Incyte became publicly traded in 1993. During the 2000s, changes in the genomics-services market and the increasing public availability of genomic information encouraged a strategic shift toward small-molecule drug discovery and development. Incyte subsequently reduced and ultimately exited its information-products activities, concentrating its resources on therapeutics. A major turning point was the development of ruxolitinib, a selective JAK1/JAK2 inhibitor. In the United States, the medicine became the foundation of the Jakafi franchise, initially serving patients with myelofibrosis and later gaining additional uses including polycythemia vera and chronic graft-versus-host disease. Incyte licensed ex-U.S. rights for ruxolitinib to Novartis, where the medicine is marketed primarily as Jakavi. This collaboration helped establish Incyte as a commercial biopharmaceutical company while retaining a strong research base. Under Hervé Hoppenot, who became chief executive officer in January 2014, Incyte expanded from a largely single-product U.S. company into a broader international business. It built European commercial operations, added products through internal development and licensing, and expanded into dermatology. Opzelura, a topical ruxolitinib formulation, became an important dermatology franchise after U.S. approvals for atopic dermatitis and nonsegmental vitiligo. The company also developed or commercialized products including Pemazyre, Iclusig, Monjuvi/Minjuvi, Zynyz and, with Syndax Pharmaceuticals, Niktimvo. Incyte’s current portfolio combines wholly owned products, co-commercialized products and partnered medicines. Jakafi and Opzelura are central U.S. products, while products such as Pemazyre, Iclusig and Minjuvi are marketed in selected international regions. Through partnerships, Incyte receives royalty or commercial economics from medicines such as Jakavi, Olumiant and Tabrecta. Its pipeline includes investigational programs in mutant calreticulin biology, JAK1 inhibition, CDK2 inhibition, KRAS G12D, TGF-beta receptor/PD-1 biology and other oncology and immunology mechanisms. The company has pursued targeted business development rather than building a large diversified conglomerate. Its acquisitions of Maxia Pharmaceuticals, Villaris Therapeutics and Escient Pharmaceuticals added discovery capabilities, clinical assets and potential treatments for autoimmune and inflammatory disease. In 2025, Incyte and Novartis settled litigation concerning the duration of U.S. Jakafi royalty obligations. The agreement required a $280 million payment for disputed royalties through December 31, 2024 and reduced the royalty rate on future U.S. Jakafi sales by 50% for a defined period. Bill Meury became Incyte’s president and chief executive officer in June 2025, succeeding Hoppenot, who retired after approximately 11 years as CEO. In 2026, the company reorganized elements of its research and commercial leadership, appointing Pablo Cagnoni as president and global head of research and development and Steven Stein as chief medical officer and head of late-stage development. Incyte remains an active public biopharmaceutical company whose identity is closely associated with targeted medicines, translational science and the commercial development of therapies for conditions with substantial unmet medical need.

History

Incyte was founded and incorporated in Delaware in 1991 by Roy A. Whitfield. Its earliest identity was not that of a conventional pharmaceutical manufacturer but of a genomics company. Incyte developed genomic information databases, research services and intellectual property used by pharmaceutical and biotechnology companies and academic researchers. The business became publicly traded in 1993, giving it access to capital during the expansion of genomics as a commercial field. During the 1990s, Incyte built capabilities in DNA sequencing, gene discovery and bioinformatics. It also recruited scientists and chemists, including personnel associated with DuPont, to support a transition from information products toward therapeutic discovery. By the early 2000s, the economics of genomic databases had weakened. Pharmaceutical consolidation reduced demand for some external research services, while the public availability of genomic data reduced the scarcity value of proprietary information products. Incyte therefore began redirecting its resources toward small-molecule drug discovery and development. The company acquired Maxia Pharmaceuticals in 2003 for approximately $42 million. The transaction expanded Incyte’s drug-discovery activities and formed part of the company’s broader effort to establish a therapeutics platform. In 2004, Incyte announced substantial changes to its information-products operations, including the closure of its Palo Alto facility and the cessation of development of products associated with that operation. In 2005, it sold certain assets and liabilities associated with its Proteome facility. These steps effectively completed the company’s withdrawal from its earlier information-services model. Incyte’s central commercial breakthrough came from ruxolitinib, a JAK1/JAK2 inhibitor that became Jakafi in the United States and Jakavi in many international markets. In 2009, Incyte entered a major collaboration and license agreement with Novartis covering ex-U.S. commercialization rights for ruxolitinib and global rights to the c-MET inhibitor that later became capmatinib. Jakafi was approved in the United States in 2011 for myelofibrosis and later gained additional indications, including polycythemia vera and chronic graft-versus-host disease. Ruxolitinib became the company’s main commercial and financial foundation. In 2013, Novartis acquired rights to capmatinib, later marketed as Tabrecta, reinforcing the importance of Incyte’s kinase-discovery platform. In January 2014, Hervé Hoppenot became CEO. During his tenure, Incyte broadened its portfolio, developed a commercial presence outside the United States and expanded beyond hematology into oncology, dermatology and inflammation. Incyte announced the relocation of its headquarters to Wilmington, Delaware, in 2013 and completed the move by the end of 2014. It established a European headquarters in Geneva in 2015 and later moved the European headquarters to Morges, Switzerland, in 2021. The company’s product expansion accelerated in the late 2010s and 2020s. Baricitinib, developed with Eli Lilly, became Olumiant and generated royalty income for Incyte. Although the U.S. FDA initially rejected the application in 2017 over dosing and safety concerns, the medicine received U.S. approval for rheumatoid arthritis in 2018. Pemigatinib became Pemazyre for selected FGFR-driven cancers and cholangiocarcinoma. Ponatinib, acquired through Incyte’s purchase of certain rights and marketed as Iclusig, strengthened the hematology portfolio. Tafasitamab, developed with MorphoSys, became Monjuvi in the United States and Minjuvi in other markets for certain forms of diffuse large B-cell lymphoma. Incyte also used its ruxolitinib expertise to enter dermatology. Opzelura, a topical formulation of ruxolitinib, was approved in the United States for atopic dermatitis in 2021 and for nonsegmental vitiligo in 2022. The vitiligo approval was especially significant because it created a new prescription treatment category for repigmentation. Opzelura subsequently became one of Incyte’s principal growth products and supported the company’s expansion into inflammation and autoimmunity. The company continued to use external innovation to augment internal research. In 2022, Incyte agreed to acquire Villaris Therapeutics and its auremolimab program, adding an immunology asset directed toward vitiligo. In 2024, it agreed to acquire Escient Pharmaceuticals for $750 million plus remaining net cash. Escient contributed oral MRGPR antagonist programs, including candidates intended for inflammatory and pruritic diseases. Incyte also entered into licensing and collaboration arrangements with companies including Syndax, MorphoSys, Eli Lilly, Novartis and others. A major clinical setback occurred in 2018 when the Phase 3 ECHO-301/KEYNOTE-252 trial of epacadostat plus Merck’s pembrolizumab failed to improve progression-free survival compared with pembrolizumab alone in metastatic melanoma. The result undermined expectations for IDO1 inhibitors and prompted changes to other epacadostat combination studies. The episode demonstrated the risks associated with Incyte’s strategy of advancing novel mechanisms in oncology, even as its ruxolitinib franchise continued to perform strongly. In 2024, Incyte and Syndax obtained U.S. FDA approval for Niktimvo, an anti-CSF-1R antibody for chronic graft-versus-host disease after failure of at least two prior systemic therapies. Niktimvo added a new biologic mechanism to Incyte’s hematology portfolio and became an important product launch in 2025. Incyte also advanced programs involving mutant calreticulin, povorcitinib, CDK2, KRAS G12D and TGF-beta receptor/PD-1 approaches. In May 2025, Incyte and Novartis settled litigation over the duration of royalty payments owed under their collaboration agreement. Incyte paid $280 million for disputed U.S. Jakafi royalties through the end of 2024 and agreed to a 50% reduction in the future U.S. royalty rate for a defined period. The settlement reduced a major legal and financial uncertainty surrounding the company’s leading product. In June 2025, Bill Meury became president and CEO, succeeding Hoppenot, who retired after approximately 11 years in the role. Meury brought prior experience at Allergan, Forest Laboratories, Karuna Therapeutics and Anthos Therapeutics. In March 2026, Incyte appointed Pablo Cagnoni as president and global head of R&D and Steven Stein as chief medical officer and head of late-stage development. These changes reflected a focus on improving research productivity, accelerating late-stage programs and integrating U.S. commercial operations. As of 2026, Incyte remained an active, publicly traded biopharmaceutical company with a global commercial footprint and a portfolio combining internally discovered medicines, licensed products and co-commercialized therapies.

  • 2026

    Research and development leadership is reorganized

    [8]

    Pablo Cagnoni is appointed president and global head of R&D, while Steven Stein becomes chief medical officer and head of late-stage development.

  • 2025

    Novartis royalty litigation is settled

    [12]

    Incyte pays $280 million for disputed U.S. Jakafi royalties through 2024 and secures a 50% reduction in future U.S. royalties for a defined period.

  • 2025

    Bill Meury becomes CEO

    [7]

    Bill Meury becomes president and chief executive officer, succeeding Hervé Hoppenot.

  • 2024

    Niktimvo receives U.S. FDA approval

    [9]

    Niktimvo is approved for chronic graft-versus-host disease after failure of at least two prior systemic therapies.

  • 2024

    Escient Pharmaceuticals is acquired

    [11]

    Incyte acquires Escient Pharmaceuticals for $750 million plus net cash, adding oral MRGPR antagonist programs.

  • 2022

    Opzelura is approved for vitiligo

    [10]

    The FDA approves Opzelura for repigmentation in nonsegmental vitiligo in adults and adolescents aged 12 and older.

  • 2022

    Villaris Therapeutics is acquired

    [17]

    Incyte agrees to acquire Villaris Therapeutics and its auremolimab program for vitiligo and autoimmune disease.

  • 2021

    Opzelura is approved for atopic dermatitis

    [16]

    The topical ruxolitinib product Opzelura is approved in the United States for atopic dermatitis, opening Incyte’s dermatology franchise.

  • 2018

    Olumiant receives U.S. approval

    [1]

    Baricitinib, developed with Eli Lilly, receives U.S. approval as Olumiant for rheumatoid arthritis after an earlier FDA rejection.

  • 2018

    Epacadostat Phase 3 program fails its primary endpoint

    [13]

    The ECHO-301/KEYNOTE-252 trial of epacadostat with pembrolizumab fails to improve progression-free survival versus pembrolizumab alone in metastatic melanoma.

Products and positioning

A science-led biopharmaceutical company focused on discovering and commercializing targeted medicines for hematology, oncology, inflammation and autoimmune diseases, with a differentiated emphasis on internally discovered assets and selective strategic partnerships.

  • Hematology and oncology medicine · 2011

    Jakafi

    Jakafi is the U.S. brand for ruxolitinib, an oral JAK1/JAK2 inhibitor and Incyte’s foundational commercial product. It is used in indications including myelofibrosis, polycythemia vera and chronic graft-versus-host disease. Incyte markets Jakafi in the United States, while ruxolitinib is licensed to Novartis outside the United States under the Jakavi brand.

  • Extended-release hematology medicine · 2026

    Jakafi XR

    Jakafi XR is an extended-release formulation of ruxolitinib designed to provide an alternative dosing presentation for patients treated for myelofibrosis, polycythemia vera and chronic graft-versus-host disease. It extends the ruxolitinib franchise with a modified-release product format.

  • Topical dermatology medicine · 2021

    Opzelura

    Opzelura is a topical cream containing ruxolitinib, a JAK1/JAK2 inhibitor. In the United States it is approved for selected patients with atopic dermatitis and nonsegmental vitiligo. The product is a major example of Incyte’s strategy of applying its JAK biology to inflammation, autoimmune disease and dermatology.

  • Oncology medicine · 2020

    Pemazyre

    Pemazyre is pemigatinib, an oral FGFR inhibitor used in selected cancers driven by fibroblast growth factor receptor abnormalities. Its approved uses include certain cholangiocarcinoma cases and myeloid or lymphoid neoplasms with FGFR1 rearrangement. Incyte markets or licenses the product across several international regions.

  • Hematology oncology medicine · 2016

    Iclusig

    Iclusig is ponatinib, a BCR-ABL tyrosine kinase inhibitor used in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. The product broadens Incyte’s hematology portfolio and is marketed by Incyte in selected non-U.S. regions.

  • Monoclonal antibody oncology medicine · 2020

    Monjuvi/Minjuvi

    Tafasitamab is marketed as Monjuvi in the United States and Minjuvi in many international markets. It is an anti-CD19 monoclonal antibody used with other therapy for certain relapsed or refractory B-cell lymphomas. Incyte obtained global development and commercialization rights through its collaboration with MorphoSys.

  • Hematology biologic · 2024

    Niktimvo

    Niktimvo is axatilimab-csfr, an anti-CSF-1R antibody developed with Syndax Pharmaceuticals. It is approved in the United States for adults and certain pediatric patients with chronic graft-versus-host disease after failure of at least two prior systemic therapies. Incyte and Syndax co-commercialize it in the United States, while Incyte holds exclusive commercialization rights outside the country.

  • Immuno-oncology medicine · 2023

    Zynyz

    Zynyz is retifanlimab-dlwr, a PD-1-directed immunotherapy. It is used in selected patients with squamous cell carcinoma of the anal canal and Merkel cell carcinoma. The product represents Incyte’s expansion into checkpoint immunotherapy and is marketed in selected territories.

  • Partnered immunology medicine · 2018

    Olumiant

    Olumiant is baricitinib, an oral JAK1/JAK2 inhibitor developed in partnership with Eli Lilly. It is approved in different jurisdictions for conditions including rheumatoid arthritis and certain other inflammatory or immune-mediated diseases. Incyte receives royalty economics from the partnership rather than serving as the primary global commercial operator.

  • Partnered oncology medicine · 2020

    Tabrecta

    Tabrecta is capmatinib, a MET inhibitor originally discovered by Incyte and licensed to Novartis. It is used for selected non-small-cell lung cancer patients whose tumors have MET exon 14 skipping alterations. Incyte receives product royalty revenue from the partnership.

Marketing campaigns

  • 2023Solve On.

    Global

    Solve On. is Incyte’s corporate purpose and brand platform, framing the company’s research and commercial work as a continuing effort to address difficult diseases and unmet medical needs. It is used across corporate communications, scientific storytelling, employee messaging and patient-focused materials.

    Outcome. The platform remains an active expression of Incyte’s corporate identity and scientific positioning.

    Source
  • 2023IncyteCARES

    United States

    IncyteCARES is a patient-support and assistance program associated with several Incyte medicines, including Jakafi, Pemazyre, Opzelura, Niktimvo, Monjuvi and Zynyz. Its activities are intended to help eligible patients navigate access, reimbursement and support services.

    Outcome. The program continues to support access and patient services for eligible patients prescribed participating medicines.

    Source

Brand decisions

  • 2026

    Research and commercial leadership reorganizationStrategy

    Background

    Incyte sought to improve R&D productivity, accelerate late-stage development and coordinate its U.S. commercial organization around long-term growth priorities.

    Action taken

    Pablo Cagnoni was appointed president and global head of R&D, Steven Stein was appointed chief medical officer and head of late-stage development, and the U.S. commercial teams were integrated into one organization.

    Aftermath

    The changes strengthened centralized scientific and commercial accountability and prioritized programs including mutant CALR, povorcitinib, CDK2, KRAS G12D and TGF-beta receptor/PD-1.

    Source

  • 2025

    Settlement of Novartis Jakafi royalty disputeOther

    Background

    Novartis initiated litigation concerning the duration of royalty payments owed under the parties’ collaboration and license agreement for Jakafi/ruxolitinib.

    Action taken

    Incyte entered a settlement agreement requiring a $280 million payment for disputed U.S. royalties through December 31, 2024 and a 50% reduction in the royalty rate on future U.S. Jakafi sales for a defined period.

    Aftermath

    The agreement resolved the litigation and reduced the ongoing royalty burden, while creating a significant one-time financial charge and cash payment.

    Settlement payment. Approximately $537.1 million of accrued royalties related to the dispute as of March 31, 2025 → $280.0 million paid to Novartis; future U.S. royalty rate reduced by 50% for a defined period (May 11, 2025)

    Source

  • 2025

    CEO succession and commercial-growth strategyStrategy

    Background

    After more than a decade of expansion under Hervé Hoppenot, Incyte initiated a planned leadership transition focused on pipeline productivity, commercial execution and sustainable growth.

    Action taken

    The board appointed Bill Meury as president and CEO and elected Julian Baker chairman, while Hoppenot remained temporarily as an adviser and director.

    Aftermath

    The transition placed a commercially experienced executive in charge as Incyte prepared for additional product launches and pipeline readouts.

    Source

  • 2024

    Acquisition of Escient PharmaceuticalsM&A

    Background

    Incyte wanted oral clinical-stage assets addressing inflammatory and pruritic diseases and sought to strengthen its inflammation and autoimmunity pipeline.

    Action taken

    Incyte agreed to acquire Escient Pharmaceuticals for $750 million plus Escient’s remaining net cash, adding MRGPR antagonist programs including EP262 and EP547.

    Aftermath

    The acquisition added orally administered clinical candidates and expanded Incyte’s discovery and development options in inflammatory disease.

    Acquisition consideration. $750 million plus remaining net cash (Announced 2024)

    Source

  • 2022

    Acquisition of Villaris TherapeuticsM&A

    Background

    Incyte sought additional biologic assets for vitiligo and autoimmune disease to complement the growing Opzelura dermatology franchise.

    Action taken

    The company agreed to acquire Villaris Therapeutics and its auremolimab program, with consideration consisting of upfront and potential milestone payments.

    Aftermath

    The transaction expanded Incyte’s inflammation and autoimmunity pipeline, particularly in vitiligo.

    Source

  • 2018

    Reassessment of epacadostat developmentOther

    Background

    The Phase 3 ECHO-301/KEYNOTE-252 study failed to show an improvement in progression-free survival for epacadostat combined with pembrolizumab versus pembrolizumab alone.

    Action taken

    Incyte and its partners stopped the pivotal melanoma development strategy and converted other planned or ongoing combination studies into randomized Phase 2 trials.

    Aftermath

    The result sharply reduced expectations for epacadostat and became a major example of the clinical risk associated with novel immuno-oncology mechanisms.

    Source

  • 2009

    Novartis collaboration for ruxolitinib and capmatinibM&A

    Background

    Incyte sought global development and commercial scale for its lead kinase programs while preserving participation in the economics of products marketed outside the United States.

    Action taken

    Incyte granted Novartis ex-U.S. commercialization rights for its lead JAK inhibitor and global commercialization rights for the c-MET inhibitor program.

    Aftermath

    The agreement supported the international development of ruxolitinib and capmatinib and created a long-term royalty relationship with Novartis.

    Source

  • 2004

    Exit from genomic information productsStrategy

    Background

    Incyte faced weakening demand for proprietary genomic information as pharmaceutical consolidation and the public availability of genomic data reduced the attractiveness of its earlier information-services model.

    Action taken

    The company closed its Palo Alto facility, stopped developing associated information products and redirected resources toward small-molecule drug discovery and development.

    Aftermath

    The decision transformed Incyte from a genomics-information business into a therapeutics-focused biotechnology company.

    Source

Recent events

  • Reported

    FDA approves Opzelura for atopic dermatitis[20]

    The FDA approved Incyte's Opzelura cream for atopic dermatitis in non-immunocompromised patients; the article says it is indicated for patients aged 12 and older whose disease is not adequately controlled with other topical prescription products.

  • Reported

    FDA approves Jakafi for chronic GVHD[21]

    The FDA approved ruxolitinib (Jakafi, Incyte) for certain patients aged 12 years or older with chronic graft-versus-host disease who failed one or two lines of systemic therapy.

  • Reported

    FDA approves Monjuvi with lenalidomide for certain DLBCL patients[22]

    MorphoSys and Incyte announced that the FDA approved Monjuvi (tafasitamab-cxix) in combination with lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant. The approval was under the accelerated approval program.

  • Unconfirmed

    Reported

    FDA approves Pemazyre for cholangiocarcinoma[23]

    The U.S. Food and Drug Administration approved Incyte's Pemazyre for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement detected by an FDA-approved test. The approval was under the accelerated approval pathway.

  • Reported

    Incyte launches the Incyte Ingenuity Award programme[24]

    Incyte opened submissions for its new annual award programme, which will fund one programme, idea or initiative each year to address an unmet need in the graft-versus-host disease community.

Read more

Sources25 sources

  1. 1Incyteen.wikipedia.org
  2. 2Incyte corporate websiteincyte.com
  3. 3Incyte pharmaceutical portfolioincyte.com
  4. 4Incyte leadershipincyte.com
  5. 5Incyte 2025 Form 10-Ksec.gov
  6. 6Incyte 2025 financial resultsinvestor.incyte.com
  7. 7Bill Meury appointed CEOinvestor.incyte.com
  8. 8Executive leadership appointmentsinvestor.incyte.com
  9. 9Niktimvo FDA approvalinvestor.incyte.com
  10. 10Opzelura vitiligo approvalinvestor.incyte.com
  11. 11Escient acquisitioninvestor.incyte.com
  12. 12Novartis royalty settlement filinginvestor.incyte.com
  13. 13Epacadostat Phase 3 updateinvestor.incyte.com
  14. 14Incyte is foundedsec.gov
  15. 15Major Novartis collaboration is signedinvestor.incyte.com
  16. 16Opzelura is approved for atopic dermatitisinvestor.incyte.com
  17. 17Villaris Therapeutics is acquiredinvestor.incyte.com
  18. 18Solve On.incyte.com
  19. 19IncyteCARESincyte.com
  20. 20FDA 批准 Opzelura 治疗特应性皮炎healio.com
  21. 21FDA批准Jakafi用于慢性移植物抗宿主病healio.com
  22. 22FDA批准Monjuvi联合来那度胺用于特定弥漫性大B细胞淋巴瘤患者finanznachrichten.de
  23. 23FDA批准Pemazyre用于胆管癌finanznachrichten.de
  24. 24Incyte推出Incyte Ingenuity Award计划pmlive.com
  25. 25FDA Approves Pemazyre to Treat Advanced Cholangiocarcinoma | CUREcuretoday.com

Cite this profile: Cite the canonical profile. /brand-wiki/incyte · Editorial policy · How profiles are compiled